General Information
In its finished dose formulation, Rivaroxaban is an oral anti-clotting substance (anticoagulant drug) which is used in the following instances: to prevent venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), in patients undergoing hip or knee replacement surgery; to prevent stroke and systemic embolism (in patients with atrial fibrillation); to treat DVT and PE and to reduce the risk of recurrent DVT and PE.
About the API
Systematic name
5-Chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide.
Trade name(s)
Xarelto
Technology
Synthetic
Molecular Formula
C19H18CIN3O5S
Molecular Weight
435.89 g/mol
Physical properties
White to yellowish power
Therapeutic category
Coagulation Inhibitors
Available formulations
Oral Solid
Regulations
CADIFA
CEP
EU DMF
Korea DMF
US DMF
CADIFA
CEP
EU DMF
Korea DMF
US DMF